Targeting the Microbiome to Improve Gut Health and Breathing Function After Spinal

Cord Injury

Jessica N. Wilson[1], Kristina A. Kigerl[2], Michael D. Sunshine[1], Chase E. Taylor[1], Sydney L.
Speed[1], Breanna C. Rose[1], Chris M. Calulot[1], Brittany E. Dong[3], Tara R. Hawkinson[4],
Harrison A. Clarke[4], Adam D. Bachstetter[1], Christopher M. Waters[3], Ramon C. Sun[4],
Phillip G. Popovich[2], Warren J. Alilain[1*]
8
Department of Neuroscience, Spinal Cord and Brain Injury Research Center (SCoBIRC), University of
Kentucky College of Medicine, Lexington, KY, USA[1]
Department of Neuroscience, Belford Center for Spinal Cord Injury, Ohio State University College of
Medicine, Columbus, OH, USA[2]
Department of Physiology, University of Kentucky College of Medicine, Lexington, KY, USA[3]
Department of Biochemistry and Molecular Biology, Center for Advanced Spatial Biomolecule Research,
University of Florida, Gainesville, FL, USA[4]
*Indicates corresponding author

Research Highlights:

• Cervical spinal cord injury (SCI) causes transient gut dysbiosis and persistent

gastrointestinal (GI) pathology.

• Treatment with probiotics after SCI leads to a healthier GI tract and improved respiratory

motor recovery.

• Probiotic treatment decreases systemic tumor necrosis factor-alpha and increases the

potential for sprouting and regeneration of neurons after SCI.

• The gut microbiome is a valid target to improve motor function and secondary visceral

health after SCI.

ABSTRACT

Spinal cord injury (SCI) is a devastating condition characterized by impaired motor and

sensory function, as well as internal organ pathology and dysfunction. This internal organ

dysfunction, particularly gastrointestinal (GI) complications, and neurogenic bowel, can reduce

the quality of life of individuals with an SCI and potentially hinder their recovery. The gut

microbiome impacts various central nervous system functions and has been linked to a number

of health and disease states. An imbalance of the gut microbiome, i.e., gut dysbiosis, contributes

to neurological disease and may influence recovery and repair processes after SCI. Here we

examine the impact of high cervical SCI on the gut microbiome and find that transient gut

dysbiosis with persistent gut pathology develops after SCI. Importantly, probiotic treatment

improves gut health and respiratory motor function measured through whole-body

plethysmography. Concurrent with these improvements was a systemic decrease in the cytokine

tumor necrosis factor-alpha and an increase in neurite sprouting and regenerative potential of

neurons. Collectively, these data reveal the gut microbiome as an important therapeutic target to

improve visceral organ health and respiratory motor recovery after SCI.

INTRODUCTION

The gut-central nervous system (CNS) axis is a bi-directional pathway where disruptions

in the normal fauna and flora of the gut, i.e. gut dysbiosis, can impair CNS function. Conversely,

CNS injury or disease can lead to gut dysbiosis. As a result of this unique interrelationship, gut

dysbiosis has been linked to a variety of neurological disorders, including depression,

amyotrophic lateral sclerosis, and cognitive decline or impairment [1-3]. In this study, we

investigated how cervical spinal cord injury can lead to gut dysbiosis, which can potentially

further lead to greater CNS dysfunction and impaired functional recovery of breathing (Figure 1

a; Schematic).

RESULTS

<u>Cervical SCI leads to acute gut dysbiosis and gastrointestinal tract pathology.</u>

Nearly 60% of all SCI cases are at the cervical level. To model this type of injury, we

used a well-characterized left C2 hemisection (LC2Hx) model of SCI in rats. This lesion reduces

diaphragm activity and impairs ventilation (Figure 1 a-b) [4,5]. In Experiment 1 (Figure 1c), adult

female Sprague Dawley rats were randomized into three experimental groups: 1) LC2Hx (n =

12), 2) surgical sham (n = 6; received post-surgical drugs and all surgical procedures except

spinal hemisection), and 3) drug control (n = 5; no surgical procedure but animals were

anesthetized and given post-surgical drugs) (Figure 1 c; Experimental design). Because

anesthesia and opioid-based analgesics affect normal gut function and the gut microbiome, a

surgical drug group was a necessary control [6,7]. To prevent bacterial transfer via coprophagia,

animals were co-housed throughout the experiment and cage-mates were in the same

experimental group.

Electromyography (EMG) of the diaphragm ipsilateral to the injury was significantly

lower in LC2Hx animals compared to surgical sham and drug control animals (Figure 1 b; One-

way ANOVA $p < 0.0001$, F = 18.77 with Tukey's posthoc LC2Hx/drug control $p = 0.0161$;

LC2Hx/surgical sham $p < 0.0001$). To determine if LC2Hx affects the gut microbiome, fecal

samples were collected from each animal of same-group co-housed rats pre-injury (i.e., 0 days

post-injury (dpi)) and on days 1, 3, 7, 14, 21, 28, 58, and 84 dpi then were prepared for 16S

rRNA sequencing of hypervariable region V4 (using 515F-806R primers). Following 16S rRNA

sequencing, we performed principal component analysis on the Bray Curtis distances of

normalized operational taxonomic units rarefied reads. There was a significant separation of the

samples from the surgical sham and LC2Hx groups in the ordination space at the operational

taxonomic unit level (Figure 2 a; PERMANOVA p = 0.001). Indeed, 16S rRNA analysis of fecal

samples prior to and following LC2Hx SCI revealed a rapid and robust change in the

composition of the gut microbiome. Notably, the Firmicutes to Bacteroidetes (F:B) ratio

increased significantly at one-day post-injury in LC2Hx but not drug control or surgical sham

animals (Figure 2 b; Two-way ANOVA time x treatment p < 0.0011; $F_{(18)}$ = 2.44). At the

phylum level, Firmicutes and Bacteroidetes bacteria constitute 90% of the gut microbiome [8,9].

An increase in the F:B ratio has been used previously to describe gut dysbiosis, or an imbalance

of pathogenic and beneficial bacteria [10]. Further, a high F:B ratio has been associated with

increased susceptibility to inflammation and obesity [10-13]. The presence of a high F:B ratio

following SCI has also been shown previously in thoracic-level mouse injury models [14].

However, this finding has been inconsistent among other preclinical models of SCI [14-16].

Although the F:B ratio returned toward pre-injury levels by three days post-injury,

histological evaluation of the gastrointestinal (GI) tract within the ileum revealed persistent and

profound gut pathology. Specifically, subepithelial blebbing and disruption of the epithelial

lining were consistent in the gut of LC2Hx SCI rats at 14 dpi (Figure 2 c. – marked by black

arrows). Subepithelial blebs found at the tips of villi, called Gruenhagen spaces [17,18], are an

indication of ischemia within the intestine and can lead to disruption and disintegration of the

epithelial lining if ischemia is prolonged [19]. To quantify this observed damage, the Chiu/Park

scoring system of GI tract pathology, which grades the degree of intestinal mucosal injury on a

scale of 0 – 5 (0 = normal mucosa; 1 = subepithelial space at the villous tip; 2 = extension of

subepithelial space with moderate lifting; 3 – massive lifting down the sides of villi, some

denuded tips; 4 = denuded villi, dilated capillaries; 5 = disintegration of lamina propria) [20].

Blinded evaluation of the tissue using the Chiu/Park scoring system of GI tract pathology

revealed no differences in the pathology and intestinal injury in sham versus LC2Hx animals,

although epithelial lifting, an indication of damage marked by black arrows, was evident in

LC2Hx animals (Figure 2 c - d; representative pie charts utilizing the Chiu/Park score). Further,

neurogenic shock and autonomic nervous system impairment following SCI can cause

hypoperfusion of visceral organs, inducing inflammation and pathological changes [21,22]. This

hypoperfusion and loss of epithelium can induce further mucosal atrophy through necrosis and

apoptosis of crypt cells. Since crypt cells provide stem cells that develop and populate the villi,

crypt destruction can result in decreased villi length [23]. We observed no change in villi length in

animals 14 days post L2CHx (Figure 2 d; unpaired, two-tailed t-test; $p = 0.5267$; $t = 0.6925$);

however, there was a strong trend in the reduction of crypt depth, although this change was not

statistically significant (Figure 2 d; unpaired, two-tailed t-test; $p = 0.0572$; $t = 2.646$).

Utilizing matrix-assisted laser desorption ionization (MALDI) imaging, we found slightly

increased levels of glycogen in the ileal tissue of LC2Hx animals compared to the surgical sham,

although this increase was not statistically significant (Figure 2 e-f; unpaired, two-tailed t-test, p

$= 0.2744$; $t = 1.265$; $R^2 = 0.2859$). Glycogen is a storage macromolecule that can influence

bacterial survival during times of extreme stress [24]. Glycogen stores allow for protein N-

glycosylation in the brain, and dysregulation can cause disease [25,26]. Additionally, glycosylation

is a hallmark of intestinal mucins, or glycoproteins, that act as the first line of defense to the

intestinal epithelium against pathogens and luminal microbiota [27]. Interestingly, microbiota have

been found to regulate host protein glycosylation, which has been linked to intestinal health and

disease [28]. This relationship further emphasizes the importance of maintaining a healthy gut

microbiome. The increasing glycogen levels in ileal tissue 14 days after LC2Hx SCI, may be a

compensatory response to increase mucin production and repair the intestinal barrier in response

to the increase in the F:B ratio that occurs immediately after SCI.

These findings expand upon previous observations of the ileum at 24 hours post-injury at

the thoracic level (T7/8 transection), where the proliferation of submucosal lymphatic tissue and

widening of mucosal epithelial cell interspaces were apparent [29]. Our findings are also consistent

with previous findings in low thoracic injuries (T10/11 contusion), where decreased mucosal

layer thickness and persistent atrophy began at 48 hours post-injury and were evident until 4

weeks post-injury [30]. A separate T10 contusion study described similar findings of disruption in

the jejunum at 3dpi, with evidence of decreased villi height, increased crypt depth, and increased

subepithelial space at the tip of villi [31]. Our results are the first to show that the high cervical

LC2Hx model can provide meaningful insights into the serious problem of bowel and GI tract

disease and pathology after SCI. Indeed, gastrointestinal complications following SCI are a

major factor impacting quality of life and account for 11% of rehospitalizations in the first year

post-SCI [32,33]. Furthermore, individuals with injuries occurring at the cervical level are more

likely to experience constipation and abdominal bloating and are more likely to require re-

hospitalization relative to individuals with lower-level injuries [34,35]. Gastrointestinal dysfunction

also can compromise intestinal barrier function, promote bacterial translocation in which

intestinal bacteria leak into the bloodstream, and contribute to systemic inflammation and

multiple organ dysfunction syndrome (MODS), further impacting recovery and quality of life of

SCI individuals [36].

Targeting gut dysbiosis improves ventilatory function and gut health.

145   Since gut dysbiosis and persistent GI tract pathology are evident after SCI, we aimed to

146 test whether oral gavage of either fecal matter transplant (from young, uninjured animals) or

147 clinical-grade probiotics would restore the gut and microbiome to their pre-injury state. Indeed,

148 previous studies have demonstrated that gut dysbiosis can induce systemic inflammation [37-39],

149 and separately, it has been shown that systemic inflammation can impair respiratory plasticity

150 [40,41].

151 Additionally, it has been established that treating neurotrauma-induced gut dysbiosis leads to

152 improved locomotor recovery, smaller lesion sizes, and prevention of anxiety-like behavior [14,42].

153 However, the impact of treating gut dysbiosis following LC2Hx on breathing function, GI tract

154 pathology, and its long-term effects remain unexplored. We aimed to answer these questions and

155 hypothesized that the dynamic changes in the gut microbiome immediately post-LC2Hx impede

156 functional recovery of breathing in the acute to the sub-acute phase of SCI. Further, we

157 hypothesized that treatment of the resulting neurotrauma-induced gut dysbiosis would improve

158 gut health and allow for a more profound recovery of breathing at acute time points post-injury.

159   Animals received fecal matter transplants (FMT) for three consecutive days, beginning

160 the day of injury, followed by bi-weekly gavage until the predetermined endpoint. This gavage

161 regimen combines two prior reports of FMT studies in rats (Schmidt et al., 2020, Kelly et al.,

162 2016) [3,42]. Treating LC2Hx animals with FMT derived from young, uninjured animals led to

163 marginal improvements in tidal volume in the first cohort of animals (Supplemental Figure 1 a; n

164 = 4/group Two-way ANOVA time x treatment p = 0.2666; $F_{(3,\ 18)}$ = 1.431). To differentiate

165 whether this change was due to alterations in peripheral lung mechanics or recovery in central

166 respiratory pathways, we assessed lung mechanics using the flexiVent system. There was an

167 increased inspiratory capacity in FMT-treated animals, which may indicate that the FMT

treatment mitigated atelectasis, or partial lung collapse (Supplemental Figure 1 b; Welch's

unpaired, two-tailed t-test; inspiratory capacity p = 0.0585; t = 2.579). Additional measures of

lung function, such as dynamic compliance, dynamic resistance, and bronchioalveolar lavage

(BAL) cells, did not differ between groups suggesting the overall lung mechanic findings did not

account for the increase in tidal volume. Therefore, these findings suggest that the change in tidal

volume may be driven centrally rather than by peripheral lung mechanic compensation.

However, when all cohorts were completed (n = 12/group), this observation of improved tidal

volume disappeared, and there were no statistically significant differences between groups in

whole-body plethysmography (WBP) or diaphragmatic EMG (diaEMG) measurements (Figure 3

a and b). Inspiratory capacity remained elevated with FMT treatment, although not significantly,

while dynamic compliance, dynamic resistance, and BAL cells remain unchanged between

groups (Supplemental Figure 1 c; Welch's unpaired, two-tailed t-test; inspiratory capacity p =

0.1122; t = 1.719).

As FMT treatment led to mixed and inconsistent improvements, we initiated an

alternative strategy utilizing a standardized probiotic treatment to mitigate gut dysbiosis based on

previous findings (Kigerl et al., 2016). We implemented a daily probiotic regimen consisting of a

low, mid, and high dose, as the literature describing dosage of probiotics given to rats was highly

variable [43-46]. The gavage volume was maintained at 0.5 ml, but the bacterial concentration

increased from 2.7 x 10^9, to 24 x 10^9, to 48 x 10^9 bacteria/dose in our rat LC2Hx model. In WBP

studies under normoxic conditions (21% O_2), animals treated with high-dose probiotics showed

the expected reduction in tidal volume but were able to increase their respiratory rate at 7 dpi

compared to the vehicle-treated group (Figure 3 c. Two-way RM ANOVA tidal volume time x

treatment p = 0.0216; F (6, 36) = 2.875; frequency time x treatment p = 0.0102; F (6, 36) =

3.341with Tukey's posthoc; tidal volume vehicle/high p = 0.0074; frequency vehicle/high p =

0.0210). Minute ventilation was maintained in the high-dose group at 7 dpi and 14 dpi due to this

compensatory increase in the respiratory rate (Figure 3 c; Two-way RM ANOVA minute

ventilation time x treatment p = 0.3032; F (6. 36) = 1.253 with Tukey's posthoc; vehicle/high

7dpi p = 0.1221; vehicle/high 14 dpi p = 0.1712). Interestingly, the vehicle, low-dose and mid-

dose animals did not display the expected SCI-dependent increase in respiratory rate and

decrease in tidal volume. To investigate this, animals were challenged under hypoxic conditions

(11% O_2). we began to see the expected SCI-dependent increase in respiratory rate, decrease in

tidal volume and compensation of minute ventilation in all probiotic treated animals (low-, mid-,

and high-dose) at 7 dpi. Interestingly, minute ventilation was increased at 7dpi in probiotic

treated animals when compared to vehicle-treated animals with the mid-dose group mounting the

highest response (Supplemental Figure 2 a; Two-way RM ANOVA with Tukey's posthoc

vehicle/mid 7dpi p = 0.1864). Examinations of lung function indicated no statistically significant

differences in lung compliance, resistance, or BAL cell counts (Supplemental Figure 2 b.).

However, the inspiratory capacity for the high-dose group was greater than all other groups and

reached significance when compared to the low-dose group (Supplemental Figure 2 b; One-way

ANOVA p = 0.0385; F = 3.452 with Tukey's posthoc high/low p = 0.0239). Interestingly, when

we evaluated diaphragm EMG, the animals in the low-dose group were able to produce the

largest burst amplitude ipsilateral to the injury compared to all other groups (Figure 3 d; One-

way ANOVA p = 0.0635; F = 2.898 with Tukey's posthoc low/vehicle p = 0.2624; low/mid p =

0.0855; low/high = 0.0984). Importantly, there were no differences in injury severity between

groups based on spared tissue analysis. This indicates that these improvements in respiratory

function were not due to a less severe injury in any particular group (Supplemental Figure 3 a –

b. One-way ANOVA p = 0.9411; F = 0.1298). While probiotic treatment improved respiratory

motor function, we did not observe changes in overall locomotor function demonstrated by the

open field test (Supplemental Figure 4). These findings suggest that probiotic treatment

following cervical spinal cord injury may improve respiratory recovery through compensatory

mechanisms by increasing the respiratory rate and amplitude of the diaphragmatic output.

In addition to improvements in ventilatory function, treatment with probiotics following

SCI also led to improved gut pathology within the ileal tissue of the small intestine. FMT

treatment produced marginal improvement in gut pathology. Less gaping between villi was

evident with FMT treatment, an indication of a healthier physiological state within the gut as

these projections are important for nutrient absorption via increased surface area of the small

intestine. There were minimal increases in villi length, although no differences in crypt depth or

Chiu/Park scores, indicating a marginal improvement in gut pathology following FMT treatment

compared to vehicle-treated animals (Figure 4 a – d; b. unpaired, two-tailed t-test villi length p =

0.2807; t = 1.107; c. unpaired, two-tailed t-test crypt depth p = 0.4801; t = 0.7189; d.

representative pie charts utilizing the Chiu/Park score). Of note, the endpoint for the FMT study

was 28 dpi in comparison to animals in Experiment 1, as well as animals in Experiment 3 (i.e.,

probiotic treatment), which both had an endpoint of 14 dpi. Because we observed the initial

improvement in total volume by 14 dpi (Supplemental Figure 1 a) but no changes in gut

pathology by 28 dpi in Experiment 2 (Figure 4 a – d), we used the 14 dpi timepoint for

Experiment 3. The extra two weeks in Experiment 2 may have allowed more healing and repair

making it difficult to detect differences with FMT treatment. Probiotic treatment resulted in

increases in villi length in a dose-dependent manner, although these differences were not

statistically significant, while there were no differences in crypt depth (Figure 4 e – h. One-way

ANOVA; villi length p = 0.1817; F = 1.808; crypt depth p = 0.8036; F = 0.3302). Additionally,

we observed an improvement in "intact" ileal tissue indicated by the Chiu/Park score with the

mid and high-dose probiotic-treated animals compared to the low-dose probiotic and vehicle-

treated animals. (Figure 4 h; representative pie charts utilizing the Chiu/Park score). Overall,

these findings suggest that treatment of gut dysbiosis acutely after SCI improves gut pathology

and potentially improves gut function.

Probiotic treatment after SCI reduces systemic inflammatory responses and increases the

sprouting and regenerative potential of neurons.

To investigate the mechanism of these functional and pathological improvements, we

obtained serum samples throughout the experiment to assess systemic inflammation. We

observed a decrease in TNF-alpha at all time points in both FMT and probiotic-treated animals

compared to vehicle-treated. This reduction was significant at 28 dpi in FMT-treated animals

(Figure 5 a; Two-way RM ANOVA time x treatment p = 0.0448; F (4, 88) = 2.548 with

Bonferroni posthoc 28 dpi p = 0.0062) and at 3 dpi in all probiotic-treated animals, regardless of

dose level (Figure 5 b; Two-way RM ANOVA time x treatment p = 0.0489; F (9, 54) = 2.068

with Tukey's posthoc 3dpi vehicle/low p = 0.0316, vehicle/mid p = 0.0152, vehicle/high p =

0.013). Additionally, there was an overall effect of FMT treatment on IL-6 serum levels, with

FMT-treated animals having lower IL-6 compared to vehicle-treated (Figure 5 a; Two-way RM

ANOVA treatment p = 0.0459; F (1, 22) = 4.478). These findings are consistent with clinical

observations. The pro-inflammatory cytokine IL-6 was found to be elevated in patients at 48

hours post-injury but decreased by 7 days post-injury [47]. Conversely, an alternate study revealed

that this increase is persistent as levels of IL-6, as well as TNF-alpha, are significantly elevated

levels in SCI patients in the post-acute (2-52 weeks post-injury) and chronic (>52 weeks post-

injury) phases of recovery compared to healthy controls [48]. Importantly for the recovery of

breathing, systemic inflammation has been shown to impair respiratory plasticity [41]. Therefore,

the reduction in systemic inflammation following treatment with probiotics may play an

important role in the improved minute ventilation observed in Figure 3 c.

We assessed if FMT or probiotic treatment could alter neuronal growth and sprouting

characteristics [49]. To do this, we harvested dorsal root ganglion neurons from the animals in

Experiments 2 and 3. Sholl analysis was used to determine the longest neurite length and the

total number of crossings or branching of neurites. The summation of neurite length (total

outgrowth) and the total number of projections from the soma were also quantified. There were

trends of increased total neurite outgrowth, number of crossings, and neurite length in FMT-

treated animals, although these changes were not statistically significant (Figures 6 a and b;

unpaired, two-tailed t-test; total outgrowth p = 0.3477; t = 0.9445 total number of crossings p =

0.2996; t = 1.056; longest neurite length p = 0.1362; t = 1.532). There was no difference in the

number of projections from the soma in FMT versus vehicle-treated animals (Figures 6 b;

unpaired, two-tailed t-test; number of projections from soma p = 0.9683; t = 0.03984). Probiotic

treatment significantly improved the number of primary projections from the soma, with the

high-dose probiotic group producing the greatest number of projections compared to all other

groups (Figure 6 a and c; One-way ANOVA p < 0.0001; F = 8.758 with Tukey's post hoc

vehicle/high p < 0.001; low/high p = 0.0002; mid/high p = 0.0067). There was also a trend of

increased total neurite outgrowth, and longest neurite length in DRGs treated with high-dose

probiotics in comparison to all other groups. Alternately, the mid-dose probiotic group produced

the largest total number of crossings (Figure 6 c). These findings indicate that treatment of gut

dysbiosis with FMT or probiotics allowed for increased neurite outgrowth potential, longer

neurite projections, greater neurite branching ability, and increased sprouting of primary

projections from the DRG soma. All of these are potential mechanisms of plasticity and recovery

either centrally or in the innervation of the GI tract.

Given the enhanced potential to increase primary projections in DRGs in probiotic-

treated animals, we next examined the extent of serotonergic sprouting below the level of injury

as a potential mechanism for improved respiratory function. Serotonin is critical in activating

silent spinal pathways that are important for recovery. We did not observe statistically significant

differences in serotonin levels at the C4 ventral horn of animals treated with probiotics versus

vehicle at 14 dpi (Supplemental Figure 5 a – b). Because we observed a significant increase in

respiratory rate following high-dose probiotic treatment at 7 dpi, examination of serotonergic

levels in the brainstem at this more acute time point may be more revealing of a potential

mechanism.

DISCUSSION

Collectively, our experiments present compelling evidence that treating SCI-induced gut

dysbiosis improves functional and pathological outcomes. We determined that this dysbiosis is

transient, and most severe immediately after LC2Hx. Interestingly, previous studies have

determined that interventions for respiratory recovery, including administration of intermittent

hypoxia and chondroitinase ABC (ChABC), are more efficacious at chronic time points post-

injury [50-52]. The immediate dysbiosis we observed may be a factor that undermines the

effectiveness of early treatment strategies. Understanding the role of the gut-CNS axis and its

influence on recovery mechanisms may improve the success of interventions at more acute time

points following SCI.

Whole-body plethysmography studies indicate that probiotic treatment improves

respiratory rate and overall minute ventilation following cervical SCI. As over half of SCI cases

occur at the cervical level, which can impair descending respiratory drive pathways, any

improvements in breathing function are of critical importance. Additionally, we found that

treatment of gut dysbiosis with probiotics also led to improvements in the pathology of ileal

tissue following SCI, demonstrated by an increase in villi length and improvements in the

Chiu/Park scoring. Gastrointestinal complications can severely impact an SCI individual's

quality of life, especially those with high-level injuries resulting in tetraplegia. Moreover, 11% of

hospitalizations in the SCI population are due to GI complications [53]. Compromise of gut barrier

function can lead to bacterial translocation (leaky gut) and potentially life-threatening

septicemia, which is sadly a leading cause of death following SCI. These realities demonstrate

the importance of maintaining gut health following SCI for overall well-being and potentially

enhancing recovery. This work further emphasizes the importance of personalized and precision

medicine through a holistic approach. Studies from our lab have previously demonstrated that

genetic background, particularly apolipoprotein E (APOE) genotype, influences respiratory

motor plasticity potential [54]. APOE status has also been robustly associated with distinct

microbiome profiles [55]. Future work evaluating the impact of genotype-associated microbiota

composition in injury models may reveal important factors that enhance recovery potential.

Mechanistically, the improvements in respiratory function may be attributed to the

reduction in systemic inflammation following the treatment of gut dysbiosis. FMT treatment

reduced the systemic IL-6 level following LC2Hx. Additionally, both FMT and probiotic

treatment reduced systemic TNF-alpha levels at all time points post-injury compared to vehicle-

treated animals. This reduction in systemic proinflammatory cytokine levels may contribute to

the observed respiratory recovery, as previous studies have demonstrated that systemic

inflammation can impair respiratory plasticity [41]. Additionally, FMT and probiotic treatment

improved the regenerative potential of neurons. The ability for plasticity and regeneration of

neurites – either centrally or peripherally - is of utmost importance for SCI recovery. Several

mechanisms to improve regenerative capacity have been employed, including enhancing the

expression of neurotrophic factors, inhibition of PTEN, administration of intermittent hypoxia,

and application of ChABC to digest inhibitory molecules within the glial scar [51,52,56-60]. We now

show that treatment of gut dysbiosis can also enhance the regenerative capacity of neurons and

can potentially be used in conjunction with these interventions. Overall, these findings provide

evidence that treatment of gut dysbiosis following SCI is a critical therapeutic target for recovery

at a holistic level.

Materials and Methods

Animals and Housing

All experiments were approved by the Institutional Animal Care and Use Committee at

the University of Kentucky. Adult female Sprague Dawley rats from Envigo were used in all

experiments and allowed to acclimate for at least one week prior to beginning experimental

procedures. Animals were co-housed in a 12-hour light/dark cycle with standard chow and water

available *ad libitum.* Animals housed together remained with their cage mate throughout the

entirety of the experiment and were in the same experimental group to avoid coprophagic cross-

colonization. For all experiments, animals were randomized into the specified groups using an

online random number generator.

Groups

The first set of experiments included three cohorts of animals that were separated into

three groups: (1) LC2Hx (n =16), (2) surgical sham (n = 12), or (3) drug control (naïve + surgical

drugs; n = 8). Animals in the third group received all surgical drugs, including isoflurane

anesthesia, and post-surgical care (same as groups one and two) but did not receive any

incisions. Group 3 was a necessary control to include because anesthesia and opioids have been

shown to impact the gut microbiome [6,7].

The second set of experiments included three cohorts of animals that all received a

LC2Hx and were separated into two treatment groups in which they received one of the

following types of oral gavage: (1) fecal matter transplant (FMT; n = 12) or (2) vehicle FMT

(control; n = 12).

The third set of experiments included two cohorts of animals that all received a LC2Hx

and were separated into four treatment groups in which they received one of the following types

of oral gavage: (1) vehicle (n = 5), (2) low dose probiotics (n = 6), (3) mid dose probiotics (n =

6), or (4) high dose probiotics (n = 5).

370
371

Fecal Matter Transplant (FMT)

Fecal samples used for the FMT were collected from young (approximately 3 months

old), healthy donor animals using an aseptic technique. Immediately after fecal sample

collection, samples were pooled and processed to make the FMT slurry solution. Fresh fecal

samples were diluted to a 1:10 concentration in sterile PBS (10%), L-cystine HCL (0.05%),

glycerol (20%), and sterile water (60%) and filtered with a 100 µm filter to remove fiber content

[42]. Vehicle-treated animals received all components of the filtered dilution solution without fecal

content. The FMT or vehicle solution was administered via oral gavage for three consecutive

days beginning on the day of injury [42], and then twice each week until the endpoint at 28 days

post-injury [3]. Each animal received a total of nine oral gavage doses with each dose consisting of

500 µL of the assigned solution.

Probiotics

The probiotic Visbiome (Lot no. 65026 and 65847) was diluted into the following

concentrations: (1) vehicle = sterile water only, (2) low dose = 15 mg (2.7 billion bacteria) in 1

ml sterile water [43,44], (3) mid dose = 130 mg (24 billion bacteria) 1 ml sterile water [45,46], or (4)

high = 260 mg (48 billion bacteria) 1 ml sterile water. The assigned concentration of Visbiome

was delivered via oral gavage beginning the day of the injury and continued once daily until the

endpoint at 14 days post-injury. Each animal received a total of fourteen oral gavage doses, with

each dose consisting of 500 µL of the assigned solution.

Left C2 Hemisection (LC2Hx)

Adult female Sprague Dawley rats were anesthetized with isoflurane gas. Once an

appropriate plane of anesthesia was met, animals were prepared for surgery by shaving and

sterilizing the surgical site with alternating 70% ethanol and betadine swabs. Ophthalmic

ointment was applied to the eyes to prevent drying throughout the procedure. While in the prone

position, an incision was made between the ears and extend approximately two inches caudally.

The underlying musculature was bluntly dissected and retracted to expose the process of the C2

lamina. The final layer of musculature was then cut and cleared away from the bone so that the

intervertebral space between C1 and C2 could be visualized. A C2 laminectomy was performed

by cutting the lamina in this space on the left and right sides of the C2 spinous process and

extending caudally until the dorsal aspect of the C2 vertebrae was removed and the spinal cord

was exposed. Micro-scissors were used to perform a durotomy and a 27-gauge hypodermic

needle was bent at a 45-degree angle and used to perform the left C2 hemisection (LC2Hx).

Briefly, anatomical landmarks were used to determine midline at the C2 level at which the

needle was inserted through the spinal cord until the ventral aspect of bone was reached and then

dragged laterally to the animal's left until completely severing the cord. Three passes were made

to ensure complete disruption of pathways on the left side. Finally, all three layers of

musculature previously dissected were sutured individually (3-0 absorbable suture) and the skin

was closed with surgical staples. All animals received buprenorphine (0.05mg/kg; immediately

and 12 hours post-surgery) and carprofen (5mg/kg; immediately, 12-, and 24 hours post-surgery)

subcutaneously. Surgical animals were monitored twice daily for the four days post-injury with

subcutaneous saline given as needed. Animals recovered for one week on a heated rack separated

from naïve animals and remained on a standard 12-hour light/dark cycle with food and water

accessible *ad libitum* prior to returning to standard housing. Welfare and weights were checked

weekly throughout the entire experiment.

Whole Body Plethysmography (WBP)

Whole Body Plethysmography (WBP) (DSI, Buxco FinePointe) was used to assess

ventilatory patterns in awake, unanesthetized rats before and after LC2Hx. At the designated

timepoints pre- and post-injury, animals were placed into individual DSI whole body

plethysmography chambers and breathing measurements were recorded every two seconds for

the duration of approximately one hour. At the beginning of each experiment, an acclimation

period of 20-minutes under normoxic conditions (21% O_2) was used to minimize atypical

respiratory patterns while initially exploring the chamber (i.e., sniffing). Immediately after, a 30-

minute baseline recording was taken under normoxic conditions (21% O_2), followed by a 10-

minute hypoxic challenge (11% O_2), and finally a 10-minute post-hypoxia recording under

normoxic conditions (21% O_2).   From the recordings, we examined respiratory rate

(breaths/min), tidal volume (mL/breath/g), and minute ventilation (mL/min/g). Food and water

were restricted while breathing measurements were taken. At the conclusion of the experiment,

animals were returned to their home cages where food and water were accessible *ad libitum.*

Diaphragmatic Electromyogram (diaEMG) Recording

Animals were anesthetized with isoflurane gas using the SomnoSuite low-flow anesthesia

system (Kent Scientific). Once an appropriate level of anesthesia was met, animals were

transferred into a faraday cage and switched to a nose cone for continued delivery of

approximately 2.4% isoflurane throughout the procedure. Animals were placed in the supine

position, and a laparotomy was performed. Upon visualization of the phrenic nerve on the

diaphragm, bipolar needle electrodes were inserted bilaterally into the dorsolateral quadrant of

the costal hemidiaphragm. Electrodes were placed in close proximity to the phrenic nerve while

being cautious to avoid piercing the nerve. Bipolar electrodes were connected to an amplifier and

data acquisition system (BMA-400 Four-channel Bioamplifier, CWE, Inc., Ardmore, PA, USA;

CED 1401 with Spike2 Data Analysis Computer Interface, CED, Cambridge, UK) to record and

analyze the electromyogram (EMG) signal. Following election insertion, the faraday cage was

closed, and a 10-minute baseline recording was measured. Immediately following the baseline

recording, three 15-second nasal occasions were performed to assess each animal's maximal

respiratory output. Sufficient time between nasal occlusions was allowed for burst amplitude to

return to approximately pre-occlusion levels. At the conclusion of the EMG recording, animals

were given ketamine/xylazine intraperitoneally while being weaned off isoflurane and

transitioned to lung health experiments.

16S rRNA Sequencing

Fecal samples were collected from study animals using an aseptic technique pre- and at

various timepoints post-LC2Hx in order to assess the gut microbiome. Samples were

immediately stored at -80°C until all samples were collected for further processing. The bacterial

16S rRNA gene was then isolated from the fecal samples using DNeasy PowerSoil Pro Kit (Ref

#47014 and 47016; Lot #169034368 and 17203302). DNA from each sample was diluted to a

concentration ranging between 1-50ng/μL and mailed to Argonne National Laboratory for

sequencing.

Read processing: 16SV4 was amplified using 515F-806R primers. Fastq files were

demultiplexed using qiime2 demux emp-paired function. Raw data were processed with qiime2.

Briefly, reads were denoised with dada trimming nucleotides based on quality plots (trim reads

when the average quality <30- see code for details). Unique reads were clustered to 99% identity

using the silva-138-99-seqs-515-806 database (ASV99% or OTUs). Chimeras were removed

using vsearch uchime-denovo function. Samples had an average of 29,245 reads (Table 1). ASVs

with <50 reads total abundance were removed since they were present in <2 samples and will not

significantly contribute to the analysis. ASVs were classified using the feature-classifier classify-

sklearn function with the silva-138-99-515-806-nb-classifier. When taxonomic classification was

not available at lower levels, the immediately following taxonomic level classification was used.

Filtered ASV 99% table (referred to as OTUs in the figures) was subsampled to analyze 15,000

reads per sample. Two samples with an unusually low number of reads were removed.

Table 0.1 Summary of 16S sequencing reads processing.

	Number (mean)	% of reads
Raw input (91 samples)	29245.0889	88.55
Denoised dada	25398.6111	86.77
ASV 100% (total)	2305	NA
ASV 99% (total)	1707	NA
ASV 99% (per individual)		
ASV 99% non-chim	1,393	NA
ASV 99% non-chim (per individual)		
ASV 99% non-chm filtered (>50 reads, >n=2; per individual)	896	NA
ASV 99% non-chm filtered (>50 reads, >n=2; per individual)	896	NA
ASV 99% non-chm filtered rarefied (15,000 reads; 89/91 samples)	896	NA
Taxonomic levels (Family)from ASV99% non-chm filtered rarefied	48	NA

Read processing: OTU abundance matrix was analyzed using vegan, and labdsv packages in R. Principal coordinate analysis was performed on rarefied reads and log10 normalized reads at the OTU and family taxonomic level. Simper analyses were performed to identify OTUs that explain most of the variation in the ordination space.

Statistical analysis: Statistical analysis of group separation in the ordination space was performed calling Permanova with the Adonis function in R. Mixed-effect time series statistical analysis of clusters and OTUs abundance was done using prism.

Sectioning and Staining
CNS

Following euthanasia at the designated times post-injury, the skull and spinal column were removed and drop-fixed in 4% paraformaldehyde (PFA) for 48 hours at 4°C. The brainstem

and cervical spinal cord were then dissected from the skull and spinal column and placed in fresh

4% PFA for an additional 24 hours at 4° and then cryoprotected in 30% sucrose at 4°C until

sectioning. The injury was used as the epicenter to create three 4mm sections (brainstem, C1/2,

and C3/4 levels). Tissue sections were then embedded in Optimal Cutting Temperature

embedding media (OCT, Sakura Tissue-TEK), and cryosections were taken at 30µm (Leica

cryostat) and placed directly onto gelatin-coated slides (Thermo Fischer Scientific) and stored at

-20°C.

Cresyl Violet

Slides were placed in CitriSolv solution prior to serially rehydrating the tissue in

decreasing concentrations of ethanol. Slides were then rinsed in distilled water, stained with

0.5% Cresyl Violet solution (Sigma Cat #C5042), rinsed in distilled water, dehydrated in the

reverse order of ethanol concentrations used, and placed in CistroSolv. Coverslips were then

applied using permount (Electron Microscopy Sciences Cat #17986-01). Slides were imaged on

a Keyence BZ-X810 microscope (Keyence Corporation of America, Itasca, IL, USA) using

bright field illumination at 2x.

Immunohistochemistry (IHC)

Frozen sections were thawed to room temperature (approximately 20°C) and placed in Heat-

Induced Epitope Retrieval at 85°C for 15 minutes. Next, slides were permeabilized with 0.4%

TritonX-100 in 1xPBS for 15 minutes prior to blocking in a solution of 3% normal goat serum,

0.2% TritonX-100 in 1xPBS for 60 minutes at room temperature. Slides were then incubated in

5-HT primary antibody diluted to 1:2000 (rabbit, ImmunoStar Cat #20080; Lot #1650001) and

NeuN primary antibody diluted to 1:5000 (mouse, ImmunoStar Cat #MCA-1B7; Lot #080522) at

4°C overnight. Next, slides were washed with 1xPBS before incubating in goat anti-rabbit

AlexaFluor 594 (Life Technologies Ref #A11037; Lot #1777945) and goat anti-mouse IgG

AlexaFluor 488 (Life Technologies Ref #A11029; Lot #1745855) for 120 minutes at room

temperature. Finally, slides received a final wash in 1xPBS and were mounted with

Fluoromount-G (SouthernBiotech Cat #0100-01). Slides were imaged on a Keyence BZ-X810

and analyzed using HALO v2.3.2089.70 (Indica Labs, Inc.).

Gut Tissue (Swiss Roll)

Following euthanasia at the designated times post-injury, the laparotomy incision made

for the diaEMG recording was expanded distally to fully visualize the abdominal cavity. The

stomach and cecum were then identified as markers for the beginning and end of the small

intestine. The small intestine was then removed and divided into thirds, with the final third

known as the ileum. The ileum was then flushed with 1xPBS and rolled into a swiss roll

configuration for sectioning as previously described [61,62]. In brief, the ileum was cut

longitudinally along the mesentery attachment to expose the lumen. A 1ml syringe plunger was

used to roll the ileum from the distal to the proximal end in the formation of the swiss roll. The

tissue was then placed in 4% PFA at 4°C for 24 hours and then moved to 70% EtOH until

paraffin embedding and sectioning at a thickness of 5µm. Slides were stained with hematoxylin

and eosin (H&E) and Alcian blue for histological assessment and summation of goblet cells

respectively. To assess intestinal injury, the Chiu/Park scoring system was employed and all

evaluators were blinded to injury or treatment. The Chiu/Park score ranges on a scale of 0 – 5 (0

= normal mucosa; 1 = subepithelial space at the villous tip; 2 = extension of subepithelial space

with moderate lifting; 3 – massive lifting down the sides of villi, some denuded tips; 4 = denuded

villi, dilated capillaries; 5 = disintegration of lamina propria) [20].

Additionally, slides underwent MALDI imaging. A Waters Synapt G2Si mass

spectrometer (Waters Corporation, Milford, MA) equipped with an Nd:YAG UV laser with a

spot size of 50um was used to detect released glycogen. A total of 300 laser spots per pixel at X

and Y coordinates were collected at a raster size of 100um. Data acquisition, spectrums were

uploaded to High-Definition Imaging (HDI) Software (Waters Corporation) for mass range

analysis from 750 to 4000m/z. HDI generated glycogen images were obtained.

Systemic Inflammation

Blood was collected via the lateral tail vein at the designated timepoints pre- and post-

injury. Serum levels of IFN-γ, IL-1β, IL-4, IL-5, IL-6, IL-10, IL-13, KC/GRO, TNF-α were

assayed using the Meso Scale Discovery (MSD) V-PLEX Proinflammatory Panel 2 Rat Kit (Lot

#K002026; Catalog #K15059D-1; Rockville, Maryland 20850-3173).

Lung Function Measurements

Rats were anesthetized by intraperitoneal injection of xylazine and ketamine. After a

tracheotomy, the rats were connected to the flexiVent system (scireq, an emka technologies

company, Montreal, QC Canada H2S 3G8). The computer-controlled small animal instrument

ventilated the rats with a tidal volume of 10 ml/kg at a frequency of 90 breaths/minute. Two

snapshots, two total lung capacity maneuvers, three more snapshots, and three pressure-volume

loop perturbations were performed for each individual subject on the flexiVent. From the second

set of snapshots after full inflation, the three acceptable recorded measurements were averaged

for dynamic compliance and dynamic resistance. An estimate of inspiratory capacity was

averaged from the three total lung capacity maneuvers.

Bronchioalveolar lavage (BAL) fluid was collected using two 5mL syringes loaded with

4mL BAL fluid buffer (sterile PBS + 0.1% EDTA). Following tracheotomy and flexiVent, the

loaded syringe was connected to the cannula and the fluid was slowly injected, then slowly

retrieved to collect BAL fluid in the same syringe. This process was repeated with the remaining

syringe. Aliquots of BAL fluid were combined in a 15mL conical tube and spun at 200 x g at 4C

for 10 minutes. Three 500uL aliquots of BAL fluid were recovered for future processing and the

remaining supernatant was discarded. The pellet was resuspended in 500uL PBS and placed on

cytospin slides (30,000 cells/slide) for differential cell counting. The following calculation was

used to determine cells/mL BAL: (Live cells (cells/mL) * volume of reconstituted pellet

(0.5mL)) / (volume of BAL recovered) = cells/mL BAL.

Open Field Chamber
At the designated timepoints pre- and post-injury, rats were placed in SuperFlex Open

Field System chambers (16x16 inches; Omnitech Electronics Inc., Colubus, OH, USA) for five

minutes and allowed to explore freely while lateral and horizonal movements were recorded.

Total distance, vertical activity count, vertical time, and center time were measured using Fusion

Software v6.5 and analyzed using GraphPad Prism v9.5.0.

Dorsal Root Ganglia (DRG) Outgrowth
DRGs were harvested at 28 DPI for FMT-treated animals, and 14 DPI for probiotic-

treated animals. After excising the spinal column from the animal, it was bisected along the

dorsal and ventral aspects to expose the DRGs. Those were then removed and cleaned of any

peripheral projections. Cleaned DRGs were then incubated with enzymes (2000U/mL

collagenase: 50U/mL dispase) overnight to digest and dissociate individual cell bodies.

Dissociated DRGs were cultured on a substratum of 0.1mg/mL Poly-D-Lysine (Life

Technologies) and 5ug/mL Laminin (Life Technologies) with Serum Free Media (Neurobasal A

media, B27 Supplement, Penicillin-Streptomycin, GlutaMAX; Life Technologies). Media was

exchanged at 24 hours to contain anti-mitotic agents Fluorodeoxyuridine (4mM) and Cytosine

Arabinoside (100☐M) to limit satellite cell contamination. Cells were allowed to grow for 3-5

days based on visible confluency, were then fixed with 4% paraformaldehyde and stained with

Beta-III Tubulin to visualize neurons for analysis.

A Keyence BZ-X810 Fluorescence Microscope was used to image take 24 random

images per animal. Image locations were chosen randomly. All cells within each image for

which the entirety of the cell outgrowth was visible was quantified via ImageJ software utilizing

the NeuronJ plug-in. This quantification includes the total neurite outgrowth, total number of

primary projections originating from the soma, the length of the longest neurite (Sholl analysis),

and total neurite branching (Sholl analysis).

605   **Statistical Analysis**
606

Experiment1: LC2Hx + Gut Microbiome Studies	
Outcome Measure	**Statistical Tests**
Gut Microbiome	Beta diversity, F:B ratio
Gut Pathology	Unpaired t-test
Gut MALDI	Unpaired t-test
DiaEMG	Unpaired t-test

Experiment 2: FMT Studies	
Outcome Measure	**Statistical Tests**
Gut Pathology	Unpaired t-test
Gut MALDI	Unpaired t-test
DiaEMG	Unpaired t-test

WBP	Two-way ANOVA RM with Bonferonni post hoc
Serum Inflammation	Two-way ANOVA RM with Bonferonni post hoc
Lung Health	Welches t-test + ID outliers
DRG Outgrowth	Unpaired t-test

Experiment 3: Probiotic Studies	
Outcome Measure	**Statistical Tests**
Gut Pathology	One-way ANOVA with Dunnett's post hoc; Kruskal-Wallace test
Gut MALDI	One-way ANOVA with Tukey's post hoc
DiaEMG	One-way ANOVA with Tukey's post hoc
CNS Injury Confirmation	One-way ANOVA with Tukey's post hoc
WBP	Two-way ANOVA RM with Tukey's post hoc
Serum Inflammation	Two-way ANOVA RM with Tukey's post hoc
Lung Health	One-way ANOVA with Tukey's post hoc
Open Field	Two-way ANOVA RM with Tukey's post hoc
DRG Outgrowth	One-way ANOVA Tukey's post hoc

619 **ACKNOWLEDGEMENTS**

620 This study was supported by funding through:

621
622 R01 NS101105 (WJA) and NIH R21 NS121966 (WJA)

623
624 NIH Training T32 NS077889 (JSN), Neurobiology of CNS Injury and Repair

625
626 Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT)

627
628 R35NS111582 (PGP and KAK) and Ray W. Poppleton Chair (PGP)

629
630 NIH grants HL151419 and HL131526, and the Kentucky Research Alliance for Lung Disease
631 (CMW)

632
633 R01AG066653, R01CA266004, R01AG078702, CureAlz fund (RCS)

635   *Research reported in this publication was supported by an Institutional Development Award (IDeA) from the*
636   *National Institute of General Medical Sciences of the National Institutes of Health under grant number P30*
637   *GM127211.*

AUTHOR CONTRIBUTIONS

J.N.W. contributed to the conception and design of experiments, acquisition, analysis, and

interpretation of data, the initial draft of the work, and revisions.

K.A.K experimental design, analysis of 16S rRNA data, and draft revision

M.D.S. experimental design, acquisition, and analysis of data, and draft revision

C.E.T. experimental design, acquisition, and analysis of whole-body plethysmography (WBP)

data, draft revision

S.L.S. acquisition, analysis, and interpretation of dorsal root ganglia (DRG) data, analysis of ileal

tissue data

B.C.R. acquisition and analysis of ileal tissue data

C.M.C. experimental design, acquisition, and analysis of data, draft revision

B.E.D. acquisition and analysis of lung function data

T.R.H. acquisition and analysis of Matrix-Assisted Laser Desorption and Ionization (MALDI)

data

H.A.C. acquisition of Matrix-Assisted Laser Desorption and Ionization (MALDI) data

A.D.B. acquisition, analysis, and interpretation of data and review of the manuscript

C.M.W conception and design of experiments, data interpretation, and review of the manuscript

R.C.S. conception and design of experiments, data interpretation, and review of the manuscript

P.G.P. conception and design of experiments, data interpretation, and review of the manuscript

W.J.A. conception and design of experiments, acquisition, analysis, and interpretation of data,

initial draft of the work, and revisions

REFERENCES

1. Zajac, D. J. *et al.* Exogenous Short Chain Fatty Acid Effects in APP/PS1 Mice. *Front Neurosci* **16**, 873549 (2022). https://doi.org:10.3389/fnins.2022.873549
2. Zeng, Q. *et al.* The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. *Sci Rep* **10**, 12998 (2020). https://doi.org:10.1038/s41598-020-69845-8
3. Kelly, J. R. *et al.* Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res* **82**, 109-118 (2016). https://doi.org:10.1016/j.jpsychires.2016.07.019
4. Porter, W. T. The Path of the Respiratory Impulse from the Bulb to the Phrenic Nuclei. *J Physiol* **17**, 455-485 (1895). https://doi.org:10.1113/jphysiol.1895.sp000553
5. National Spinal Cord Injury Statistical Center. *Traumatic Spinal Cord Injury Facts and Figures at a Glance*, <https://www.nscisc.uab.edu/public/Facts%20and%20Figures%202022%20-%20English%20Final.pdf> (2022).
6. Serbanescu, M. A. *et al.* General Anesthesia Alters the Diversity and Composition of the Intestinal Microbiota in Mice. *Anesth Analg* **129**, e126-e129 (2019). https://doi.org:10.1213/ANE.0000000000003938
7. Gicquelais, R. E., Bohnert, A. S. B., Thomas, L. & Foxman, B. Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. *Sci Rep* **10**, 19471 (2020). https://doi.org:10.1038/s41598-020-76570-9
8. Rinninella, E. *et al.* What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* **7** (2019). https://doi.org:10.3390/microorganisms7010014
9. Arumugam, M. *et al.* Enterotypes of the human gut microbiome. *Nature* **473**, 174-180 (2011). https://doi.org:10.1038/nature09944
10. Spychala, M. S. *et al.* Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome. *Ann Neurol* **84**, 23-36 (2018). https://doi.org:10.1002/ana.25250
11. Tremaroli, V. & Backhed, F. Functional interactions between the gut microbiota and host metabolism. *Nature* **489**, 242-249 (2012). https://doi.org:10.1038/nature11552
12. Turnbaugh, P. J. *et al.* An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* **444**, 1027-1031 (2006). https://doi.org:10.1038/nature05414
13. Ley, R. E. *et al.* Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* **102**, 11070-11075 (2005). https://doi.org:10.1073/pnas.0504978102
14. Kigerl, K. A. *et al.* Gut dysbiosis impairs recovery after spinal cord injury. *J Exp Med* **213**, 2603-2620 (2016). https://doi.org:10.1084/jem.20151345
15. Doelman, A. *et al.* Correction to: Characterization of the gut microbiome in a porcine model of thoracic spinal cord injury. *BMC Genomics* **22**, 879 (2021). https://doi.org:10.1186/s12864-021-08202-z
16. Myers, S. A. *et al.* Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis

and endotoxemia. *Neurobiol Dis* **124**, 353-363 (2019).
https://doi.org:10.1016/j.nbd.2018.12.008
17 Park, P. O., Haglund, U., Bulkley, G. B. & Falt, K. The sequence of development of
intestinal tissue injury after strangulation ischemia and reperfusion. *Surgery* **107**, 574-
580 (1990).
18 Chiu, C. J., McArdle, A. H., Brown, R., Scott, H. J. & Gurd, F. N. Intestinal mucosal lesion
in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. *Arch*
Surg **101**, 478-483 (1970). https://doi.org:10.1001/archsurg.1970.01340280030009
19 Grootjans, J., Lenaerts, K., Buurman, W. A., Dejong, C. H. & Derikx, J. P. Life and death at
the mucosal-luminal interface: New perspectives on human intestinal ischemia-
reperfusion. *World J Gastroenterol* **22**, 2760-2770 (2016).
https://doi.org:10.3748/wjg.v22.i9.2760
20 Quaedackers, J. S. *et al.* An evaluation of methods for grading histologic injury following
ischemia/reperfusion of the small bowel. *Transplant Proc* **32**, 1307-1310 (2000).
https://doi.org:10.1016/s0041-1345(00)01238-0
21 Kakimoto, Y., Matsushima, Y., Tsuboi, A., Seto, Y. & Osawa, M. Nonocclusive mesenteric
ischemia secondary to spinal cord injury: an autopsy case. *Spinal Cord Ser Cases* **7**, 37
(2021). https://doi.org:10.1038/s41394-021-00402-9
22 Besecker, E. M., Deiter, G. M., Pironi, N., Cooper, T. K. & Holmes, G. M. Mesenteric
vascular dysregulation and intestinal inflammation accompanies experimental spinal
cord injury. *Am J Physiol Regul Integr Comp Physiol* **312**, R146-R156 (2017).
https://doi.org:10.1152/ajpregu.00347.2016
23 Hang, C. H., Shi, J. X., Li, J. S., Wu, W. & Yin, H. X. Alterations of intestinal mucosa
structure and barrier function following traumatic brain injury in rats. *World J*
Gastroenterol **9**, 2776-2781 (2003). https://doi.org:10.3748/wjg.v9.i12.2776
24 Strange, R. E. Bacterial "glycogen" and survival. *Nature* **220**, 606-607 (1968).
https://doi.org:10.1038/220606a0
25 Young, L. E. A. *et al.* In situ mass spectrometry imaging reveals heterogeneous glycogen
stores in human normal and cancerous tissues. *EMBO Mol Med* **14**, e16029 (2022).
https://doi.org:10.15252/emmm.202216029
26 Sun, R. C. *et al.* Brain glycogen serves as a critical glucosamine cache required for protein
glycosylation. *Cell Metab* **33**, 1404-1417 e1409 (2021).
https://doi.org:10.1016/j.cmet.2021.05.003
27 Roberti, M. P., Rauber, C., Kroemer, G. & Zitvogel, L. Impact of the ileal microbiota on
colon cancer. *Semin Cancer Biol* **86**, 955-966 (2022).
https://doi.org:10.1016/j.semcancer.2021.09.016
28 Pelaseyed, T. & Hansson, G. C. Membrane mucins of the intestine at a glance. *J Cell Sci*
133 (2020). https://doi.org:10.1242/jcs.240929
29 Liu, J. *et al.* Study of bacterial translocation from gut after paraplegia caused by spinal
cord injury in rats. *Spine (Phila Pa 1976)* **29**, 164-169 (2004).
https://doi.org:10.1097/01.BRS.0000107234.74249.CD
30 Kabatas, S. *et al.* Neural and anatomical abnormalities of the gastrointestinal system
resulting from contusion spinal cord injury. *Neuroscience* **154**, 1627-1638 (2008).
https://doi.org:10.1016/j.neuroscience.2008.04.071

31   Liu, X. *et al.* Hyperbaric Oxygen Treatment Improves Intestinal Barrier Function After
Spinal Cord Injury in Rats. *Front Neurol* **11**, 563281 (2020).
https://doi.org:10.3389/fneur.2020.563281
32   Jaglal, S. B. *et al.* Health system factors associated with rehospitalizations after
traumatic spinal cord injury: a population-based study. *Spinal Cord* **47**, 604-609 (2009).
https://doi.org:10.1038/sc.2009.9
33   Anderson, K. D. Targeting recovery: priorities of the spinal cord-injured population. *J
Neurotrauma* **21**, 1371-1383 (2004). https://doi.org:10.1089/neu.2004.21.1371
34   Krause, J. S. & Saunders, L. L. Risk of hospitalizations after spinal cord injury: relationship
with biographical, injury, educational, and behavioral factors. *Spinal Cord* **47**, 692-697
(2009). https://doi.org:10.1038/sc.2009.16
35   Ng, C. *et al.* Gastrointestinal symptoms in spinal cord injury: relationships with level of
injury and psychologic factors. *Dis Colon Rectum* **48**, 1562-1568 (2005).
https://doi.org:10.1007/s10350-005-0061-5
36   Deitch, E. A., Xu, D. & Kaise, V. L. Role of the gut in the development of injury- and shock
induced SIRS and MODS: the gut-lymph hypothesis, a review. *Front Biosci* **11**, 520-528
(2006). https://doi.org:10.2741/1816
37   Thevaranjan, N. *et al.* Age-Associated Microbial Dysbiosis Promotes Intestinal
Permeability, Systemic Inflammation, and Macrophage Dysfunction. *Cell Host Microbe*
21, 455-466 e454 (2017). https://doi.org:10.1016/j.chom.2017.03.002
38   Rizzetto, L., Fava, F., Tuohy, K. M. & Selmi, C. Connecting the immune system, systemic
chronic inflammation and the gut microbiome: The role of sex. *J Autoimmun* **92**, 12-34
(2018). https://doi.org:10.1016/j.jaut.2018.05.008
39   Brandsma, E. *et al.* A Proinflammatory Gut Microbiota Increases Systemic Inflammation
and Accelerates Atherosclerosis. *Circ Res* **124**, 94-100 (2019).
https://doi.org:10.1161/CIRCRESAHA.118.313234
40   Agosto-Marlin, I. M., Nichols, N. L. & Mitchell, G. S. Systemic inflammation inhibits
serotonin receptor 2-induced phrenic motor facilitation upstream from BDNF/TrkB
signaling. *J Neurophysiol* **119**, 2176-2185 (2018). https://doi.org:10.1152/jn.00378.2017
41   Huxtable, A. G., Smith, S. M., Vinit, S., Watters, J. J. & Mitchell, G. S. Systemic LPS
induces spinal inflammatory gene expression and impairs phrenic long-term facilitation
following acute intermittent hypoxia. *J Appl Physiol (1985)* **114**, 879-887 (2013).
https://doi.org:10.1152/japplphysiol.01347.2012
42   Schmidt, E. K. A. *et al.* Fecal transplant prevents gut dysbiosis and anxiety-like behaviour
after spinal cord injury in rats. *PLoS One* **15**, e0226128 (2020).
https://doi.org:10.1371/journal.pone.0226128
43   Li, Y. J., Dai, C. & Jiang, M. Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral
Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway. *Dig Dis Sci* **64**, 1182-1192
(2019). https://doi.org:10.1007/s10620-018-5416-6
44   Dai, C. *et al.* VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-
kappaB pathway in rat model of DSS-induced colitis. *Mol Cell Biochem* **374**, 1-11 (2013).
https://doi.org:10.1007/s11010-012-1488-3

45   Chang, B. *et al.* The protective effect of VSL#3 on intestinal permeability in a rat model
of alcoholic intestinal injury. *BMC Gastroenterol* **13**, 151 (2013).
https://doi.org:10.1186/1471-230X-13-151
46   Wang, H. *et al.* Mechanism of Probiotic VSL#3 Inhibiting NF-kappaB and TNF-alpha on
Colitis through TLR4-NF-kappaB Signal Pathway. *Iran J Public Health* **48**, 1292-1300
(2019).
47   de Mello Rieder, M. *et al.* Serum Biomarkers and Clinical Outcomes in Traumatic Spinal
Cord Injury: Prospective Cohort Study. *World Neurosurg* **122**, e1028-e1036 (2019).
https://doi.org:10.1016/j.wneu.2018.10.206
48   Davies, A. L., Hayes, K. C. & Dekaban, G. A. Clinical correlates of elevated serum
concentrations of cytokines and autoantibodies in patients with spinal cord injury. *Arch
Phys Med Rehabil* **88**, 1384-1393 (2007). https://doi.org:10.1016/j.apmr.2007.08.004
49   Omura, T. *et al.* Robust Axonal Regeneration Occurs in the Injured CAST/Ei Mouse CNS.
Neuron **86**, 1215-1227 (2015). https://doi.org:10.1016/j.neuron.2015.05.005
50   Golder, F. J. & Mitchell, G. S. Spinal synaptic enhancement with acute intermittent
hypoxia improves respiratory function after chronic cervical spinal cord injury. *J Neurosci*
25, 2925-2932 (2005). https://doi.org:10.1523/JNEUROSCI.0148-05.2005
51   Warren, P. M. *et al.* Rapid and robust restoration of breathing long after spinal cord
injury. *Nat Commun* **9**, 4843 (2018). https://doi.org:10.1038/s41467-018-06937-0
52   Alilain, W. J., Horn, K. P., Hu, H., Dick, T. E. & Silver, J. Functional regeneration of
respiratory pathways after spinal cord injury. *Nature* **475**, 196-200 (2011).
https://doi.org:10.1038/nature10199
53   Holmes, G. M. & Blanke, E. N. Gastrointestinal dysfunction after spinal cord injury. *Exp
Neurol* **320**, 113009 (2019). https://doi.org:10.1016/j.expneurol.2019.113009
54   Strattan, L. E. *et al.* Novel Influences of Sex and APOE Genotype on Spinal Plasticity and
Recovery of Function after Spinal Cord Injury. *eNeuro* **8** (2021).
https://doi.org:10.1523/ENEURO.0464-20.2021
55   Zajac, D. J., Green, S. J., Johnson, L. A. & Estus, S. APOE genetics influence murine gut
microbiome. *Sci Rep* **12**, 1906 (2022). https://doi.org:10.1038/s41598-022-05763-1
56   Gutierrez, D. V., Clark, M., Nwanna, O. & Alilain, W. J. Intermittent hypoxia training after
C2 hemisection modifies the expression of PTEN and mTOR. *Exp Neurol* **248**, 45-52
(2013). https://doi.org:10.1016/j.expneurol.2013.05.013
57   Warren, P. M. & Alilain, W. J. Plasticity Induced Recovery of Breathing Occurs at Chronic
Stages after Cervical Contusion. *J Neurotrauma* **36**, 1985-1999 (2019).
https://doi.org:10.1089/neu.2018.6186
58   Grill, R., Murai, K., Blesch, A., Gage, F. H. & Tuszynski, M. H. Cellular delivery of
neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery
after spinal cord injury. *J Neurosci* **17**, 5560-5572 (1997).
https://doi.org:10.1523/JNEUROSCI.17-14-05560.1997
59   Liu, Y. *et al.* Transplants of fibroblasts genetically modified to express BDNF promote
regeneration of adult rat rubrospinal axons and recovery of forelimb function. *J Neurosci*
19, 4370-4387 (1999). https://doi.org:10.1523/JNEUROSCI.19-11-04370.1999
60   Liu, K. *et al.* PTEN deletion enhances the regenerative ability of adult corticospinal
neurons. *Nat Neurosci* **13**, 1075-1081 (2010). https://doi.org:10.1038/nn.2603

61   Bialkowska, A. B., Ghaleb, A. M., Nandan, M. O. & Yang, V. W. Improved Swiss-rolling
838   Technique for Intestinal Tissue Preparation for Immunohistochemical and
839   Immunofluorescent Analyses. *J Vis Exp* (2016). https://doi.org:10.3791/54161
840   62   Moolenbeek, C. & Ruitenberg, E. J. The "Swiss roll": a simple technique for histological
841   studies of the rodent intestine. *Lab Anim* **15**, 57-59 (1981).
842   https://doi.org:10.1258/002367781780958577
843

LIST OF FIGURES

Figure 1. Injury model and experimental design.

a, Schematic representation of the LC2Hx model disrupting the respiratory pathway. **b**, Quantification of diaphragm burst amplitude as a percent maximum activity contralateral and ipsilateral to the LC2Hx and histological images indicating the injury severity for each group (blue = drug control (n = 5), green = sham (n = 6), red = LC2Hx (n = 12)). As expected, the LC2hx produced a significant decrease in the burst amplitude on the ipsilateral side of the lesion (One-way ANOVA $p < 0.0001$ with Tukey's posthoc LC2Hx/drug control $p = 0.0161$, LC2Hx/ surgical sham $p < 0.0001$). **c.** Experimental design; Experiment 1: Evaluating gut dysbiosis following LC2Hx, groups: drug control (n = 5), surgical sham (n = 6), LC2hx (n = 12); Experiment 2: Fecal matter transplant (FMT) treatment following LC2Hx, groups: vehicle (FMT slurry without fecal component, n = 12) or FMT-treated (n = 12), three consecutive gavages beginning day of surgery followed by biweekly gavage until endpoint; Experiment 3: Probiotic treatment following LC2Hx, groups: vehicle (sterile water, n = 5), low-dose probiotic = 15 mg with 2.7 x 10^9 bacteria/dose (n = 6), mid-dose probiotic = 24 x 10^9 bacteria/dose (n = 6), high-dose probiotic = 24 x 10^9 bacteria/dose (n = 5) gavage daily beginning day of injury.

Figure 2. Cervical SCI leads to acute dysbiosis and GI tract pathology.

a, Principal coordinate analysis (PCoA) on Bray Curtis distances of normalized operational taxonomic units (OTUs) rarefied reads for all timepoints pre- and post-injury (pink = LC2Hx; blue = surgical sham; permnova p = 0.0001). **b,** 16S rRNA sequencing data revealed a significant increase in the Firmicutes:Bacteriodetes ratio at 1 dpi in the LC2hx group (Two-way RM ANOVA p < 0.0011). **c - d**, Histological representations of ileal tissue pathology at 14 dpi revealed no change in villi length, although depth (was 3/group; unpaired t-test, two-tailed; villi length p = 0.52; crypt depth p = 0.058). Pie charts representing pathological changes in ileal tissue utilizing the Chiu/Park scoring system in the sham versus LC2Hx animals at 14 days post-LC2Hx revealed no differences between groups, although epithelial lifting, an indication of damage marked by black arrows, was evident in the LC2Hx group (0 – 0.5 = intact (green); 1.0 – 2.5 = mild (yellow); 3 – 5 = severe (red)). **e**, MALDI imaging revealed that LC2hx leads to metabolic dysregulation of glycogen in the ileum at 14 dpi; *M/z* 1013.3213 (6 linear chains of glucose) displayed as representative image of glycogen. **f,** Quantification of MALDI imaging (n = 3/group; unpaired, two-tailed t-test; p = 0.2744; R^2 = 0.285). Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

Figure 3. Targeting gut dysbiosis improves ventilatory function.

A, Quantification of WBP measurements (respiratory rate, tidal volume, and minute ventilation) and **b,** diaEMG studies following LC2Hx and treatment with vehicle (blue; n = 12) or FMT (red; n = 12) revealed marginal differences between groups. c – d, Quantification of WBP and diaEMG studies following LC2Hx and treatment with vehicle (blue; n = 5), low-dose (purple; n = 6), mid-dose (green; n = 6), or high-dose (red; n = 5) probiotics. **c,** Treatment with probiotics following LC2Hx revealed a significant increase in the respiratory rate in the high-dose probiotics versus vehicle-treated animals at 7 dpi (Two-way RM ANOVA with Tukey's posthoc vehicle/high 7dpi $p = 0.0340$). Conversely, there was a significant decrease in tidal volume in the high-dose probiotic versus vehicle-treated animals at 7 dpi and high-dose versus low-dose probiotic-treated animals at 14 dpi (Two-way RM ANOVA with Tukey's posthoc high/vehicle 7 dpi $p = 0.0121$ and high/low 14 dpi $p = 0.0496$) Although not significantly different, all probiotic treated animals were able to maintain a higher minute ventilation than vehicle-treated animals at all time points post-injury. **d,** diaEMG studies revealed no significant differences between any treatment groups in the contralateral or ipsilateral diaphragm following LC2Hx, although the low-dose probiotic treated group was able to mount a greater burst amplitude compared to all other groups (One-way ANOVA with Tukey's posthoc low/vehicle $p = 0.2624$, low/mid $p = 0.0855$, low/high $p = 0.0984$). Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

Figure 4. Targeting gut dysbiosis improves gut health.

a, Representative histological images of ileal tissue stained with Alcian blue in vehicle (blue) and FMT-treated (red) animals at 28 days post-LC2Hx at 2x (left) and 5x (right - enlarged window). **b – d,** Quantification of **b,** villi length (unpaired t-test p = 0.2807), **c,** crypt depth (unpaired t-test p = 0.4801), and injury severity represented by the **d,** Pie charts representing pathological changes in ileal tissue utilizing the Chiu/Park score in the vehicle versus FMT-treated animals at 28 days post-LC2Hx revealed minimal changes between groups (0 – 0.5 = intact (green); 1.0 – 2.5 = mild (yellow); 3 – 5 = severe (red)). **e,** Representative histological images of ileal tissue stained with Alcian blue in vehicle and high-dose probiotic-treated animals at 14 days post-LC2Hx at 2x (left) and 5x (right - enlarged window). **f – h,** Quantification of ileal histology at 14 days post-LC2Hx in vehicle (blue), low-dose (purple), mid-dose (green), or high-dose (red) probiotic-treated animals. **f,** Quantification of villi length revealed a trend of increased length as the probiotic dose increased compared to vehicle, although these differences were not significant (One-way ANOVA with Dunnett's posthoc p = 0.1817; vehicle/low p = 0.5316; vehicle/mid p = 0.5906; vehicle/high p = 0.0791). **g,** Quantification of crypt depth revealed no significant difference between groups (One-way ANOVA with Dunnett's posthoc p = 0.8036; vehicle/low p > 0.999; vehicle/mid p = 0.9362; vehicle/high p = 0.7399). **h,** Pie charts representing pathological changes in ileal tissue utilizing the Chiu/Park score in the vehicle, low-, mid-, or high-dose probiotic-treated animals at 14 days post-LC2Hx revealed an improvement in pathology (0 – 0.5 = intact (green); 1.0 – 2.5 = mild (yellow); 3 – 5 = severe (red)). Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

Figure 5. Treating gut dysbiosis reduces the systemic inflammatory response.

a, Quantification of proinflammatory cytokines in the serum vehicle (blue) and FMT-treated (red) animals pre-injury and at 3, 7, 14, and 28 days post-LC2Hx. Of the nine cytokines tested, TNF-alpha and IL-6 both revealed treatment effects and decreased at all time points post-injury (Two-way ANOVA TNF-alpha $p = 0.0216$ and IL-6 $p = 0.0459$). Bonferroni's posthoc analysis revealed that this decrease was significant in TNF-alpha levels in FMT-treated compared to vehicle-treated animals at 28 dpi ($p = 0.0062$).

b, Quantification of proinflammatory cytokines in the serum of vehicle (blue), low-dose (purple), mid-dose (green), or high-dose (red) probiotic animals pre-injury and at 3, 7, and 14 days post-LC2Hx. TNF-alpha revealed a treatment effect and was decreased in all probiotic treated animals compared to vehicle-treated at all timepoints. (Two-way ANOVA TNF-alpha $p = 0.0066$). Tukey's posthoc analysis revealed this decrease to be significant at 3dpi in all probiotic-treated groups compared to vehicle (vehicle/low $p = 0.0316$, vehicle/mid $p = 0.0152$, vehicle/high $p = 0.0139$). Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

Figure 6. Probiotic treatment following SCI increases the sprouting and regenerative potential of neurons.

a, Representative images for DRGs treated with vehicle (blue) or FMT (red) (Experiment 2) and vehicle (blue), low- (purple), mid- (green), or high-dose (red) probiotics (Experiment 3). **b,** Mean ± SD of total neurite outgrowth of DRGs *in vitro* measured for *in vivo* FMT versus vehicle-treated animals. There was no significant difference in total outgrowth (p-value = 0.3477). Mean ± SD of the total number of primary projections growing from DRG soma *in vitro* for FMT versus vehicle-treated animals. There was no significant difference in the total number of primary projections growing from the DRG soma (p-value = 0.9683). Mean + SD of the length of the longest measured neurite extending from the DRG. The length of the longest neurite was increased in DRGs from FMT-treated animals (0.1362). Mean + SD of the total number of neurite crossings of the concentric rings in a Scholl analysis of DRGs *in vitro* for animals treated with FMT or vehicle *in vivo*. The total number of crossings was increased in animals treated with FMT (p-value = 0.2996), thus indicating that total neurite branching was increased in animals treated with FMT. **c,** Probiotic treatment did not cause a significant difference in the total neurite outgrowth of DRGs in comparison to vehicle-treated (p-value = 0.0986), although there was a trend towards increased total neurite outgrowth of DRGs from animals treated with high-dose versus low-dose probiotics (p-value = 0.0644, difference = 4.452 +/- 1.792). The total number of projections of high-dose probiotics was significantly increased compared to vehicle (2.290 ± 0.5143; p-value < 0.0001****), low-dose probiotics (2.262 ± 0.5351; p-value = 0.0002***), and mid-dose probiotics (1.650 ± 0.5056; p-value = 0.0067**).

The length of the longest neurite increased as the concentration of the probiotic treatment increased (p-value = 0.4284). The total number of crossings increased for the DRGs of animals treated with the mid and high concentrations of probiotics (p-value = 0.1645), thus indicating that total neurite branching was increased by the mid and high probiotic concentrations. Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

Supplemental Figure 1. FMT treatment does not improve ventilatory function following LC2Hx.

a, Quantification of WBP measurements (respiratory rate, tidal volume, and minute ventilation) in cohort 1 (n = 4 animals/group) following LC2Hx and treatment with vehicle (blue) or FMT (red) revealed marginal differences between groups, although there appeared to be some improvement in the tidal volume of FMT-treated animals at 14 and 28 dpi. (Two-way ANOVA treatment p = 0.5745). **b,** Lung function measurements (compliance, resistance, inspiratory capacity, and BAL cell counts) in cohort 1 (n = 4 animals/group) revealed no significant differences between groups (Welch's t-test compliance p = 0.8278, resistance p = 0.9783, inspiratory capacity p = 0.0585, BAL cell counts p = 0.2699). **c,** Lung function measurements (compliance, resistance, inspiratory capacity, and BAL cell counts) in cohorts 1 and 2 (n = 8 animals/group) revealed no significant differences between groups (Welch's t-test compliance p = 0.7348, resistance p = 0.7676, inspiratory capacity p = 0.1122, BAL cell counts p = 0.9321). Bars represent mean ± SD. Bolded text indicates a p-value < 0.05.

a

b

Supplemental Figure 2. Hypoxic whole-body plethysmography and lung mechanic measurements following SCI and probiotic treatment.

a, Quantification of WBP measurement (respiratory rate, tidal volume, and minute ventilation) under hypoxic conditions (11% oxygen) in vehicle (blue), low-dose (purple), mid-dose (green), or high-dose (red) probiotic animals pre-injury, 7, and 14 days post-LC2Hx revealed marginal differences between groups. There appeared to be some improvement in the minute ventilation of probiotic-treated animals at 7 dpi, as all probiotic-treated groups produced an increase in minute ventilation compared to vehicle, although this increase was not statistically significant (Two-way ANOVA treatment $p = 0.3555$). **b,** Lung function measurements revealed no significant differences in compliance, resistance, or BAL cell counts (One-way ANOVA compliance $p = 0.1118$, resistance $p = 0.5558$, BAL cell counts $p = 0.2409$). Inspiratory capacity differed between groups, with the high-dose group significantly higher than the low-dose group (One-way ANOVA inspiratory capacity $p = 0.0585$, Tukey's posthoc low/high $p = 0.0239$). Bars represent mean $\pm$ SD. Bolded text indicates a p-value < 0.05.

a

Vehicle	Low	Mid	High
37.3% Spared Tissue	28.9% Spared Tissue	24.6% Spared Tissue	39.1% Spared Tissue

b

Supplemental Figure 3. Confirmation of LC2Hx in Experiment 3: Probiotic treatment following LC2Hx.

a, Representative images of cresyl violet staining at the level of injury (spinal level C2) in vehicle, low-dose, mid-dose, and high-dose probiotic-treated animals 14 days post-LC2Hx.

b, Quantification of spared tissue indicated no significant differences between groups (vehicle = blue, low = purple, mid = green, high = red) at the level of injury, demonstrating that all animals were equally injured (One-way ANOVA p = 0.9411). Therefore, improvements observed in outcome measures are not attributed to a less severe injury. Bars represent mean ± SD.

Supplemental Figure 4. Probiotics treatment does not affect locomotor activity following LC2Hx.

Evaluation of locomotion was assessed in activity chambers pre-injury and at 7 and 14 dpi. **a,** All probiotic-treated groups demonstrated an increase in total distance traveled at both time points post-injury, although this trend was not statistically significant (Two-way ANOVA treatment p = 0.3973). **b,** Center time was higher in vehicle-treated animals at 7 dpi compared to all probiotic groups, although not significantly (Two-way ANOVA treatment p = 0.0723). Bonferroni post hoc analysis revealed no significant differences between groups at any time point. **c – d,** There were no significant differences between groups in **c,** vertical activity count, or **d,** vertical time (Two-way ANOVA vertical activity count p = 9616, vertical time p = 8164). As expected, there was a time effect in all measurements, as all animals were injured. Bars represent mean ± SD. Bolded text indicates a p-value < 0.05

a

b

Supplemental Figure 5. Probiotic treatment does not alter serotonin levels at the level of the phrenic motor nucleus.

a, Representative images of 5-HT (serotonin) staining at the level of the phrenic motor nucleus (spinal level C4) in vehicle, low-dose, mid-dose, and, high-dose probiotic-treated animals 14 days post-LC2Hx (5-HT = red, NeuN = green). **b,** Quantification of 5-HT staining indicated no significant differences between groups (vehicle = blue, low = purple, mid = green, high = red) at the level of C4 on the contralateral or ipsilateral side of injury (One-way ANOVA contralateral p = 0.4413, ipsilateral p = 0.7821). Evaluation of the ipsilateral side as a percentage of the contralateral side indicated that all probiotic groups had more serotonin than vehicle-treated, although this trend was not statistically significant (One-way ANOVA p = 0.6941). Bars represent mean ± SD.